Evidence map›Paper›PMID 38981998›Full record

ArticleEuropean radiology experimental2024

High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades.

Ines Horvat-Menih, Hao Li, Andrew N Priest, Shaohang Li, Andrew B Gill, Iosif A Mendichovszky, Susan T Francis, Anne Y Warren, Brent O'Carrigan, Sarah J Welsh and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology experimental, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03741426 (WIndow of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in REnal Cell Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03741426 phase2unknown statusnot on this map

WIndow of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in REnal Cell Cancer

TypeinterventionalSponsorCCTU- Cancer ThemeRan2020 to 2025Enrolled60ConditionsRenal Cell CancerArmsOlaparib, Cediranib, Durvalumab
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ines Horvat-MenihDepartment of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK. ih357@cam.ac.uk.ORCID http://orcid.org/0000-0002-1373-6944
Hao LiDepartment of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.
Andrew N PriestDepartment of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Shaohang LiThe Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.
Andrew B GillDepartment of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.
Iosif A MendichovszkyDepartment of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.
Susan T FrancisSir Peter Mansfield Imaging Centre, University of Nottingham, Nottingham, UK.
Anne Y WarrenDepartment of Pathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Brent O'CarriganDepartment of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Sarah J WelshDepartment of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
James O JonesDepartment of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Antony C P RiddickDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
James N ArmitageDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Thomas J MitchellDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Grant D StewartDepartment of Urology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Ferdia A GallagherDepartment of Radiology, University of Cambridge, Cambridge, CB2 0QQ, UK.

Funding

Cancer Research UK RQAG/119
6 · The paper itself

Abstract

backgroundClinical imaging tools to probe aggressiveness of renal masses are lacking, and T2-weighted imaging as an integral part of magnetic resonance imaging protocol only provides qualitative information. We developed high-resolution and accelerated T2 mapping methods based on echo merging and using k-t undersampling and reduced flip angles (TEMPURA) and tested their potential to quantify differences between renal tumour subtypes and grades.

methodsTwenty-four patients with treatment-naïve renal tumours were imaged: seven renal oncocytomas (RO); one eosinophilic/oncocytic renal cell carcinoma; two chromophobe RCCs (chRCC); three papillary RCCs (pRCC); and twelve clear cell RCCs (ccRCC). Median, kurtosis, and skewness of T2 were quantified in tumours and in the normal-adjacent kidney cortex and were compared across renal tumour subtypes and between ccRCC grades.

resultsHigh-resolution TEMPURA depicted the tumour structure at improved resolution compared to conventional T2-weighted imaging. The lowest median T2 values were present in pRCC (high-resolution, 51 ms; accelerated, 45 ms), which was significantly lower than RO (high-resolution; accelerated, p = 0.012) and ccRCC (high-resolution, p = 0.019; accelerated, p = 0.008). ROs showed the lowest kurtosis (high-resolution, 3.4; accelerated, 4.0), suggestive of low intratumoural heterogeneity. Lower T2 values were observed in higher compared to lower grade ccRCCs (grades 2, 3 and 4 on high-resolution, 209 ms, 151 ms, and 106 ms; on accelerated, 172 ms, 160 ms, and 102 ms, respectively), with accelerated TEMPURA showing statistical significance in comparison (p = 0.037).

conclusionsBoth high-resolution and accelerated TEMPURA showed marked potential to quantify differences across renal tumour subtypes and between ccRCC grades.

trial registrationClinicalTrials.gov, NCT03741426 . Registered on 13 November 2018. RELEVANCE STATEMENT: The newly developed T

Indexed as

Kidney NeoplasmsMagnetic Resonance ImagingNeoplasm GradingAdultAgedCarcinoma, Renal CellFemaleHumansMaleMiddle AgedCarcinoma (renal cell)Kidney cortexKidney neoplasmsMagnetic resonance imagingOncocytoma (renal)

Identifiers

PMID38981998
PMCPMC11233479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.